Drugs / nal-IRI
nal-IRI
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04662112 | Jun 2021 → Oct 2023 | pancreatic ductal adenocarcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02785068 | Jul 2016 → May 2018 | colorectal cancer | Merrimack Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT06662006 | Mar 2024 → Dec 2027 expected | malignant pancreatic neoplasm | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT04150640 | Jul 2020 → Dec 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT03986294 | Dec 2019 → Jan 2022 | malignant pancreatic neoplasm | Academic Medical Center - University of Amsterdam | Unknown | Missed primary |
| Phase 2 | NCT04009876 | May 2019 → Oct 2022 | rectal cancer | HM Hospitales | Completed | No outcome recorded |
| Phase 2 | NCT03043547 | Oct 2017 → Dec 2021 | cholangiocarcinoma, gallbladder carcinoma | AIO-Studien-gGmbH | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07689539 | Sep 2026 → Jul 2028 expected | malignant pancreatic neoplasm | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06494514 | Apr 2024 → Apr 2027 expected | pancreatic exocrine neoplasm | Du Juan | Recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT07033689 Background | Jan → Dec 2026 expected | pancreatic ductal adenocarcinoma | SONIRE Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04731467 Background | Mar 2021 → Sep 2024 | colorectal adenocarcinoma, malignant pancreatic neoplasm, melanoma, non-small cell lung carcinoma +2 | Famewave Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT07028424 Background | Jul 2025 → Jul 2029 expected | pancreatic ductal adenocarcinoma | GERCOR - Multidisciplinary Oncology Cooperative Group | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06669078 Background | Oct 2024 → Oct 2027 expected | pancreatic exocrine neoplasm | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nal-IRI | “NASOX regimen contains nal-IRI, which has recently been proven effective in pancreatic cancer.” NCT04662112 ↗12“Nal-IRI+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.” NCT06669078 ↗ “Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1” NCT07689539 ↗ |
| Known as | Irinotecan liposome | “nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)” NCT03043547 ↗ |
| Known as | liposomal irinotecan | “This study aimed to determine the optimal second-line treatment strategy in patients with metastatic pancreatic cancer, hypothesizing that liposomal irinotecan (nal-IRI)...” PMID 41921365 ↗ Mar 20263“Liposomal irinotecan (nal-IRI) is the novel agent enhancing the drug delivery of irinotecan and approved for the management of gemcitabine-progressed metastatic pancreatic...” NCT04662112 ↗ “liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT” NCT06662006 ↗ “nal-IRI \[Liposomal Irinotecan\]” NCT04009876 ↗ |
| Route | Intravenous | “receive intravenous infusions of nanoliposomal irinotecan (70 mg/m2), fluorouracil (2400 mg/m2), and leucovorin (400 mg/m2) every 2 weeks” PMID 38870977 ↗ Jun 2024 |